Vaxcyte, Inc. (PCVX) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Vaxcyte reported revenue of $0. Net income was -$766.6M, or -$5.63 per diluted share. Operating activities generated -$655.6M of cash, leaving -$669.3M of free cash flow. At fiscal year end, Vaxcyte held $3.00B in total assets against $317.2M in total liabilities, including $174.0M of cash and equivalents.
Open the full interactive Vaxcyte financials → Quarterly statements, key ratios, valuation history and price charts.
Vaxcyte Key Stats
| Share Price | $66.80 |
|---|---|
| Market Cap | $9.65B |
| 52-Week Range | $40.32 – $73.82 |
| Shares Outstanding | 144.5 million (basic, 2026 Q2) |
Vaxcyte Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$89.6M | -$103.7M | -$232.3M | -$468.0M | -$569.5M | -$923.7M |
| Pre-Tax Income | -$89.2M | -$100.1M | -$223.5M | -$402.3M | -$463.9M | -$766.6M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$89.2M | -$100.1M | -$223.5M | -$402.3M | -$463.9M | -$766.6M |
| Diluted EPS | -$3.02 | -$1.93 | -$3.44 | -$4.14 | -$3.80 | -$5.63 |
Vaxcyte Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$212.8M | -$246.5M | -$320.6M | -$284.3M |
| Diluted EPS | -$1.56 | -$1.81 | -$2.30 | -$1.97 |
Vaxcyte Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $386.2M | $69.0M | $834.7M | $397.5M | $387.9M | $174.0M |
| Current Assets | $389.0M | $256.3M | $942.6M | $1.10B | $1.79B | $1.63B |
| Total Assets | $392.8M | $324.3M | $1.01B | $1.41B | $3.51B | $3.00B |
| Current Liabilities | $46.9M | $28.7M | $40.5M | $145.3M | $140.2M | $205.8M |
| Total Liabilities | $47.0M | $40.3M | $52.6M | $167.4M | $205.5M | $317.2M |
| Shareholders' Equity | $345.8M | $284.0M | $953.6M | $1.24B | $3.31B | $2.69B |
Vaxcyte Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$46.6M | -$121.4M | -$170.6M | -$296.8M | -$452.6M | -$655.6M |
| Cash From Investing | -$1.1M | -$212.3M | $74.6M | -$773.3M | -$2.01B | $437.4M |
| Cash From Financing | $374.9M | $17.8M | $861.5M | $639.8M | $2.45B | $2.0M |
| Free Cash Flow | -$47.8M | -$127.9M | -$176.4M | -$312.9M | -$475.1M | -$669.3M |
Figures from Vaxcyte's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Vaxcyte financials page for every line item.
Vaxcyte Company Profile
| Ticker | PCVX |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Carlos, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001649094 |
Frequently Asked Questions
What was Vaxcyte's revenue in fiscal 2025?
Vaxcyte (PCVX) reported revenue of $0 for fiscal 2025.
What is Vaxcyte's annual revenue history?
Vaxcyte's annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Vaxcyte's net income in fiscal 2025?
Vaxcyte reported net income of -$766.6M for fiscal 2025.
What was Vaxcyte's earnings per share (EPS) in fiscal 2025?
Vaxcyte's diluted EPS was -$5.63 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Vaxcyte generate in fiscal 2025?
Vaxcyte generated -$669.3M of free cash flow in fiscal 2025.
What was Vaxcyte's revenue last quarter?
In its most recent reported quarter (2026 Q2), Vaxcyte reported revenue of $0.
How many shares of Vaxcyte are outstanding?
Vaxcyte reported a weighted average of 144.5 million basic shares outstanding in 2026 Q2.
What is Vaxcyte's market cap?
Based on its latest closing price, Vaxcyte (PCVX) has a market capitalization of about $9.65B.
When does Vaxcyte's fiscal year end?
Vaxcyte's fiscal year end, as registered with the SEC, is December 31.
Where is Vaxcyte headquartered?
Vaxcyte lists its business address in San Carlos, California in its SEC filings.
Vaxcyte Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →